Brief: Lavipharm H1 Net Profit Decreases To €2.4 Million
17/09/2026 15:36
BRIEF-Lavipharm H1 Net Profit Decreases To €2.4 Million Sept 17 (Reuters) - Lavipharm SA LPHr.AT:
H1 NET PROFIT AT €2.4 MILLION VERSUS €2.6 MILLION YEAR AGO
H1 EBITDA AT €7.1 MILLION VERSUS €7.7 MILLION YEAR AGO
H1 SALES AFTER REBATES AND CLAWBACK RISE 28.9% TO €34.4 MILLION
CFO SAYS SALES FOR SECOND HALF OF 2026 ARE EXPECTED TO BE SIGNIFICANTLY HIGHER THAN FIRST-HALF SALE
EXPECTS COMMERCIAL LAUNCH OF DUROGESIC TO BEGIN IN EARLY OCTOBER
Further company coverage: [LPHr.AT]
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587785269;))
Recent news on Lavipharm SA
See all newsBrief: Lavipharm H1 Net Profit Decreases To €2.4 Million
Brief: Lavipharm Q1 Earnings Before Tax From Continuing Operations €1.41 Million, Up 28.6% YoY
Brief: Lavipharm To Acquire Durogesic Pain Patch Rights From Janssen For $12.0 Million
Brief: Lavipharm SA FY 2025 Earnings After Tax EUR 6.0 Million Versus EUR 9.0 Million Year Ago
Brief: Lavipharm 9-Month Net Profit Down To EUR 3.5 Million